Relatively low primary drug resistant tuberculosis in southwestern Ethiopia

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Abebe, Gemeda ^a,b   Abdissa, Ketema ^a   Abdissa, Alemseged ^a   Apers, Ludwig ^c   Agonafir, Mulualem ^d   De Jong, Bouke C ^c   Colebunders, Robert ^b,c  

^a JIMMA UNIVERSITY   (Ethiopia)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d ETHIOPIAN PUBLIC HEALTH INSTITUTE   (Ethiopia)

Author keywords

Drug resistance; Ethiopia; Jimma; Tuberculosis

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DRUG EFFECT; ETHIOPIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MIXED INFECTION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RISK; RISK ASSESSMENT; RISK FACTOR; SPUTUM; STATISTICAL MODEL;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; COINFECTION; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; ETHIOPIA; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; PREVALENCE; RIFAMPIN; RISK ASSESSMENT; RISK FACTORS; SPUTUM; STREPTOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84860663602     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-225     Document Type: Article

References (25)

1. World Health Organization, WHO Report 2011. Global tuberculosis control 2011 Geneva: World Health Organization 2011
2. Extensively drug-resistant tuberculosis: current challenges and threats. Jain A, Mondal R, FEMS Immunol Med Microbiol 2008 53 145 150 10.1111/j.1574-695X.2008.00400.x 18479439 (Pubitemid 351832181)
3. World Health Organization, IUATLD, Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/2008.394 Geneva: World Health Organization 2008
4. Tuberculosis: a global overview of the situation today. Sudre P, ten Dam G, Kochi A, Bull World Health Organ 1992 70 149 159 1600578
5. Primary drug resistance in newly diagnosed smear positive tuberculosis patients in Addis Ababa, Ethiopia. Asmamaw D, Seyoum B, Makonnen E, Atsebeha H, Woldemeskel D, Yamuah L, Addus H, Aseffa A, Ethiop Med J 2008 46 367 374 19271401
6. Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital. Meskel DW, Abate G, Lakew M, Goshu S, Aseffa A, Ethiop Med J 2008 46 219 225 19271385
7. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs. Abate G, Miorner H, Ahmed O, Hoffner SE, Int J Tuberc Lung Dis 1998 2 580 584 9661826 (Pubitemid 28320067)
8. Prevalence of antituberculosis drug resistance in Harar Tuberculosis Centre, Ethiopia. Mitike G, Kebede D, Yeneneh H, East Afr Med J 1997 74 158 161 9185412
9. Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia. Agonafir M, Lemma E, Wolde-Meskel D, Goshu S, Santhanam A, Girmachew F, Demissie D, Getahun M, Gebeyehu M, van Soolingen D, Int J Tuberc Lung Dis 2010 14 1259 1265 20843416
10. World Health Organization, Guidance on provider initiated HIV testing and counseling in health facilities Geneva: World Health Organization 2007
11. World Health Organization, WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Guidelines for surveillance of drug resistance in tuberculosis Geneva: WHO 2 2003 WHO/CDS/TB/2003.320-WHO/CDS/CSR/RMD/2003.3
12. Kent P, G K, Public health mycobacteriology: A guide for the level III laboratory. U. S. department of Health and Human Services. Centres for Disease Control, Atlanta, Ga. Centres for Disease Control Atlanta: Ga 1985
13. Siddiqi SH, Rüsch-Gerdes S, MGITTMProcedure Mannual Geneva, Switzerland: Foundation for Innovative New Diagnostics 2006
14. Prevalence of drug resistant tuberculosis in Arsi Zone, Ethiopia. Gebeyehu M, Lemma E, Eyob G, Eth J Health Dev 2001 15 11 16
15. Identification of drug susceptibility pattern and mycobacterial species in sputum smear positive pulmonary tuberculosis patients with and without HIV co-infection in north west Ethiopia. Mekonen M, Abate E, Aseffa A, Anagaw B, Elias D, Hailu E, Idh J, Moges F, Wolde-Amanuel Y, Asrat D, et al. Ethiop Med J 2010 48 203 210 21073081
16. Susceptibility of a series of routine sputum samples for antituberculosis chemotherapy in Gweru. Apers LM, Chihota V, Zimbabwe. S Afr Med J 2004 94 282 (Pubitemid 38585222)
17. Rates of anti-tuberculosis drug resistance in Kampala-Uganda are low and not associated with HIV infection. Lukoye D, Cobelens FG, Ezati N, Kirimunda S, Adatu FE, Lule JK, Nuwaha F, Joloba ML, PLoS One 2008 6 16130
18. Mycobacterium tuberculosis complex drug resistance pattern and identification of species causing tuberculosis in the West and Centre regions of Cameroon. Assam-Assam JP, Penlap VB, Cho-Ngwa F, Tedom JC, Ane-Anyangwe I, Titanji VP, BMC Infect Dis 2011 11 94 10.1186/1471-2334-11-94 21496268
19. Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. Matthys F, Rigouts L, Sizaire V, Vezhnina N, Lecoq M, Golubeva V, Portaels F, Van der Stuyft P, Kimerling M, PLoS One 2009 4 7954 10.1371/journal.pone.0007954 19956770
20. Molecular identification of streptomycin monoresistant Mycobacterium tuberculosis related to multidrug-resistant W strain. Bifani P, Mathema B, Campo M, Moghazeh S, Nivin B, Shashkina E, Driscoll J, Munsiff SS, Frothingham R, Kreiswirth BN, Emerg Infect Dis 2001 7 842 848 11747697 (Pubitemid 33121591)
21. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP, Lancet Infect Dis 2009 9 153 161 10.1016/S1473-3099(09)70041-6 19246019
22. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rusch-Gerdes S, Karimovich HA, Kebede Y, Mills C, PLoS One 2007 2 1126 10.1371/journal.pone.0001126 17987113 (Pubitemid 351594020)
23. Multidrug-resistant tuberculosis management in resource-limited settings. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blondal K, Caminero JA, Cegielski JP, Danilovits M, Espinal MA, et al. Emerg Infect Dis 2006 12 1389 1397 10.3201/eid1209.051618 17073088 (Pubitemid 44455215)
24. Evaluation of Capilia TB assay for rapid identification of Mycobacterium tuberculosis complex in BACTEC MGIT 960 and BACTEC 9120 blood cultures. Muchwa C, Akol J, Etwom A, Morgan K, Orikiriza P, Mumbowa F, Odong PR, Kateete DP, Eisenach KD, Joloba ML, BMC Res Notes 2012 5 44 10.1186/1756-0500-5-44 22260090
25. Performance assessment of the Capilia TB assay and the BD ProbeTec ET system for rapid culture confirmation of Mycobacterium tuberculosis. Wang JY, Lee LN, Lai HC, Hsu HL, Jan IS, Yu CJ, Hsueh PR, Yang PC, Diagn Microbiol Infect Dis 2007 59 395 399 10.1016/j.diagmicrobio.2007.06.010 17878064 (Pubitemid 350184223)